Bioprocessing
Arrakis touts paper on RNA-targeted small molecules
Arrakis Therapeutics is touting the publication of a new paper that demonstrates the capabilities of its proprietary photoaffinity labeling/next-generation sequencing technology for the systemic identification of binding sites in RNA molecules as a method to facilitate the discovery of RNA-targeted small molecule medicines. The research was published in the American Chemical Society's ACS Chemical Biology.
Molecular barcoding of DNA identifies rare mutations in stem cells
Scientists have developed a new next-generation sequencing technique using molecular barcodes that can accurately detect a single genetic mutation in a pool of 10,000 cells. The researchers applied the approach to CRISPR-Cas9 genome editing to search for undesirable mutations caused by the platform. The research and methods were published in Genome Biology on August 24.  Discuss
NCI, Cancer Research U.K. fund project to spur cancer research
The U.S. National Cancer Institute (NCI) has partnered with Cancer Research U.K. to fund Cancer Grand Challenges, an international initiative to support new ideas for cancer research.
Partner Therapeutics begins COVID-19 clinical trial for Leukine
Partner Therapeutics has enrolled the first patient in its iLeukPulm clinical trial, a randomized phase II study of inhaled sargramostim (Leukine) in hospitalized COVID-19 patients with acute hypoxemia.
Carisma, NYU Langone to develop Vpx lentiviral vector
Carisma Therapeutics has entered into a scientific research and licensing agreement with NYU Langone Health to attain exclusive rights to develop and commercialize a Vpx lentiviral vector globally for all indications.
EpiVax licenses COVID-19 vaccine to EVT
EpiVax has licensed its COVID-19 vaccine candidate, EPV-CoV-19, to EpiVax Therapeutics (EVT), formerly known as EpiVax Oncology.
Catalent to support AstraZeneca COVID-19 vaccine manufacturing
Catalent and AstraZeneca have signed an agreement to expand manufacturing support for an adenovirus vector-based COVID-19 vaccine from the University of Oxford.
Expression Therapeutics develops stem cell lentiviral gene therapy
Expression Therapeutics has developed a potentially curative gene therapy candidate for familial hemophagocytic lymphohistiocytosis type 3.
RNAimmune gets $2.35M for mRNA therapeutics, vaccines
RNAimmune has secured $2.35 million in seed round financing from multiple venture capital firms to advance its COVID-19 vaccine RV1730 program and neoantigen-based cancer vaccine programs.
Moderna discusses supplying 80M doses of mRNA-1273 to EU
Moderna is in discussions with the European Commission to supply 80 million doses of messenger RNA (mRNA)-1273, Moderna's COVID-19 vaccine candidate, as part of the commission's goal to secure early access to safe and effective COVID-19 vaccines for Europe.
Conferences
ESMO Virtual Congress 2020
September 14-29
Online
BioProcess International West
September 21-25
Online
BioProcess International
September 21-25
Online
ASGCT 2020 Policy Summit
September 23-25
Online
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter